Some historically high-yielding sectors aren't necessarily your best stomping grounds, says Morningstar's Josh Peters.

Underneath the noise, private sector employment is improving, but we're far from a full recovery.

'Buy and hold' doesn't mean never sell, rebalance, or reallocate, says Morningstar's Christine Benz.

Despite recent worries over a slowdown, the manufacturing sector still has some legs, which could boost the overall economy, too.

Morningstar's Christine Benz offers stock and fund ideas to boost the yield in the margins of your portfolio.

If smart capital allocation is good for the market, most big mergers probably aren't, argues Morningstar's Pat Dorsey.

Morningstar's Christine Benz on the runup in Treasury and real estate funds, large versus small caps, and where fund investors are putting and pulling their money.

Morningstar's Pat Dorsey outlines the major competitive advantages that give superior companies the power to stay on top.

Get Scott Burns' ETF ideas for yield-seekers, plus his take on the week's housing and M&A news.

Following Lou Simpson's retirement from Geico, Morningstar's Paul Larson sizes up Buffett's possible successors.

Morningstar's Paul Justice and Mike Rawson discuss the differences among the major index families and how to manage market exposures and taxes using ETF holdings.

Pessimism over the competitive environment is well priced into the stock of this traditional grocer, says Morningstar's Michelle Chang.

The data is likely to remain discouraging for a while longer, says Morningstar's Bob Johnson. Get his take on the underlying trends and Friday's GDP report.

Many closed-end funds offer enticing yields, but investors must do their homework to choose and use these investments wisely.

The bonds of this boring, but consistently profitable company have a near-term upside catalyst, says Morningstar analyst Dan Rohr.

Morningstar's Christine Benz highlights the importance of coordinating benefit timing, do-overs, and spousal benefits to maximize your payout.

Patient yield seekers may get a better payoff by targeting names with strong dividend-growth prospects.

Morningstar markets editor Jeremy Glaser won't stop the presses for M&A news, retail sales, unemployment, bond popularity, or Blockbuster's blues.

Worries about the FDA's ruling on the relative safety of menthol cigarettes have left Lorillard's bonds looking attractively priced according to Morningstar's Dave Sekera.

The USCI Fund offers individuals a new, and possibly better, approach to access the commodity market but risks remain, according to Morningstar's Ben Johnson.

Bonds may have done well over the last decade but dividend paying stocks like J&J may be the best bet for the next ten years says Morningstar's Josh Peters.

With increased savings, consumers could be spending more than they are, says Morningstar's Bob Johnson.

Travel, food, and technology names look attractive as China's domestic consumer market grows, says Schroders' Virginie Maisonneuve, a subadvisor for Vanguard International Growth.

The Morningstar StockInvestor editor suggests one pick for fighting inflation and three stock ideas that should hold up well if deflation hits.

Morningstar's Sunit Gogia thinks the software as a service provider has a bright future but that investors are underestimating challenges facing the firm.

When you buy any kind of an asset in a less liquid form, you're going to get it at a discount, which means higher returns, says Yale professor, Zebra Capital CIO and Ibbotson founder Roger Ibbotson.

There are a few reason margins could stay higher today than the historical average, says Morningstar's Pat Dorsey.

Morningstar's Bob Johnson on the factors behind the recent economic slowdown and what may get growth back on track.

Fixed-income investors need to look beyond TIPS when constructing an inflation resistant portfolio says Morningstar's Marta Norton.

Strong, stable cash flows should allow these firms to keep paying shareholders a hefty percentage of their earnings says Morningstar's Josh Peters.

Low fees can have big impact on your bottom line, says Morningstar's Christine Benz, who recommends looking for funds below these key fee breakpoints.

The CEO's departure will be a setback for HP but the firm is strong enough to carry on without him according to Morningstar's Michael Holt.

The small-cap biotech firm's experimental diabetes drug could make it a M&A target says Morningstar's Karen Anderson.

Exposure to non-U.S. markets and business spending has boosted earnings, says Morningstar's Pat Dorsey. Plus: the big fly in the ointment for banks.

Although the Fed's remaining toolbox is constrained, investors can stack the deck in their favor with high-quality stock picks, says Morningstar's Bill Bergman.

Morningstar markets editor Jeremy Glaser looks at the week's big statements from policymakers, politicians, and CEOs.

Facing dwindling drug pipelines, plenty of big pharma firms may end up jumping into the bidding for Genzyme, according to Morningstar's Karen Andersen.

Even if stocks tread water for another decade, dividends will still provide a real return to investors says Morningstar's Josh Peters.

Morningstar analyst Vishnu Lekraj says jittery corporations are adding temp workers at a decent clip but aren't ready to hire permanent staff en masse just yet.

These newer investment types and services have brought convenience, discipline, and lower costs to investors.